{
    "clinical_study": {
        "@rank": "146330", 
        "arm_group": [
            {
                "arm_group_label": "T2DM with No Renal Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Participants with T2DM and with no renal impairment"
            }, 
            {
                "arm_group_label": "T2DM with Mild Renal Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Participants with T2DM and with mild renal impairment"
            }, 
            {
                "arm_group_label": "T2DM with Moderate Renal Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Participants with T2DM and with moderate renal impairment"
            }, 
            {
                "arm_group_label": "T2DM with Severe Renal Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Participants with T2DM and with severe (not on dialysis) renal impairment"
            }, 
            {
                "arm_group_label": "Healthy Participants with No Renal Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Healthy participants with no renal impairment"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to evaluate the effect of renal impairment on the pharmacokinetics,\n      pharmacodynamics, safety and tolerability  of ertugliflozin in participants with type 2\n      diabetes mellitus (T2DM) and in healthy participants with normal renal function."
        }, 
        "brief_title": "Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Renal Impairment", 
            "Type 2 Diabetes Mellitus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body Mass Index (BMI) of approximately 18 to 40 kg/m^2\n\n          -  Stable renal function\n\n          -  Male or female not of reproductive potential\n\n          -  Female of reproductive potential must agree or have their partner agree to use 2\n             acceptable methods of contraception\n\n          -  Healthy subjects determined to be healthy by investigator screening\n\n          -  T2DM participants have a diagnosis of T2DM as per American Diabetes Association\n             guidelines\n\n          -  T2DM participants to be on a stable anti-hyperglycemic regimen with no new drug or\n             drug dosage within 8 weeks of study participation.  Variations in daily dose of\n             insulin up to 10% are permitted.\n\n        Exclusion Criteria:\n\n          -  A positive urine drug screen for drugs of abuse or recreational drugs\n\n          -  Pregnant or nursing females\n\n          -  History of abuse of alcohol or illicit drugs\n\n          -  Significant renal or urinary disease within 6 months of study participation\n\n          -  History of malignancy within the past 5 years basal cell carcinoma of the skin or\n             cervical cancer in situ\n\n          -  History of human immunodeficiency virus (HIV)\n\n          -  History of blood dyscrasias or any disorders causing hemolysis or unstable red blood\n             cells\n\n          -  Any acute disease state (eg, , vomiting, fever, diarrhea) within 7 days before study\n             participation\n\n          -  Treatment with an investigational drug within 30 days of study participation\n\n          -  Use of herbal supplements within 28 days prior to study participation\n\n          -  Any clinically significant malabsorption condition\n\n          -  Blood donation (excluding plasma donations) of approximately 1 pint within 56 days\n             prior to study participation\n\n          -  History of sensitivity to ertugliflozin or other Sodium-Glucose co-Transporter 2\n             (SGLT2) inhibitors\n\n          -  History of sensitivity to heparin or heparin-induced thrombocytopenia\n\n          -  Unwilling or unable to comply with the study Lifestyle Guidelines\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease including clinically relevant and significant drug allergies\n\n          -  Use of prescription drugs (hormonal methods of birth control are allowed), vitamins\n             and dietary supplements within 7 days of study participation\n\n          -  For T2DM participants, history of type 1 diabetes mellitus or a history of\n             ketoacidosis\n\n          -  For T2DM participants, clinically significant electrocardiogram abnormality\n\n          -  For T2DM participants, history of myocardial infarction, unstable angina, coronary\n             revascularization, stroke or transient ischemic attack within 3 months of study\n             participation\n\n          -  For T2DM participants, heart failure defined as New York Heart Association Functional\n             Class III-IV\n\n          -  For T2DM participants, renal allograft recipients\n\n          -  For T2DM participants, requiring dialysis\n\n          -  For T2DM participants, strict fluid restriction\n\n          -  For T2DM participants, urinary incontinence\n\n          -  For T2DM participants, acute renal disease\n\n          -  For T2DM participants, significant hepatic, cardiac, or pulmonary disease or\n             clinically nephrotic\n\n          -  For T2DM participants, prescription and over-the-counter medication that is not taken\n             according to a stable regimen for 7 days before study participation\n\n          -  For T2DM participants, on metformin should not be enrolled if their baseline renal\n             function is outside the approved product labeling\n\n          -  For T2DM participants receiving any of the following medications within 7 days of\n             study participation: 1. Other SGLT2 inhibitors (eg, dapagliflozin, canagliflozin,\n             empagliflozin); 2. Other injectable anti-hyperglycemic agents including pramlintide\n             or Glucagon-like peptide-1 (GLP-1) analogues; 3. Any immunosuppressive drugs,\n             including cyclosporine, tacrolimus, sirolimus; 4. Oral corticosteroids (note that\n             inhaled, nasal and topical corticosteroids are permitted); 5. Any potent\n             drug-metabolizing enzyme-inducing drug, including rifampin, phenytoin, and\n             carbamazepine; 6. Probenecid, valproic acid, gemfibrozil."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948986", 
            "org_study_id": "8835-009", 
            "secondary_id": "B1521023"
        }, 
        "intervention": {
            "arm_group_label": [
                "T2DM with No Renal Impairment", 
                "T2DM with Mild Renal Impairment", 
                "T2DM with Moderate Renal Impairment", 
                "T2DM with Severe Renal Impairment", 
                "Healthy Participants with No Renal Impairment"
            ], 
            "description": "Single oral administration of tablets.", 
            "intervention_name": "Ertugliflozin", 
            "intervention_type": "Drug", 
            "other_name": "MK-8835"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 1, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Call for Information (Investigational Site 1002)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "DeLand", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32720"
                    }, 
                    "name": "Call for Information (Investigational Site 1004)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Call for Information (Investigational Site 1001)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Paul", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55114"
                    }, 
                    "name": "Call for Information (Investigational Site 1003)"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase 1, Non-Randomized, Open-Label, Single Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Plasma Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "Up to 96 hours after study drug administration"
            }, 
            {
                "measure": "Number of Participants Experiencing an Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 19"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948986"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Urinary Glucose Excretion Over 24 Hours (UGE0-24hr)", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 hours"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}